Literature DB >> 27503578

Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.

K Kubo1, M Ohara1, M Tachikawa1, L H Cavallari2, M T M Lee3,4, M S Wen5, M G Scordo6, E A Nutescu7, M A Perera8, A Miyajima1, N Kaneko1, V Pengo9, R Padrini10, Y T Chen4, H Takahashi1.   

Abstract

Using population pharmacokinetic analysis (PPK), we attempted to identify predictors of S-warfarin clearance (CL(S)) and to clarify population differences in S-warfarin pharmacokinetics among a cohort of 378 African American, Asian and white patients. Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h-1, P<0.01). The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites. These results indicate warfarin dosing algorithms should be evaluated in each respective ethnic population. Further study of a large African American cohort will be necessary to confirm the present findings.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27503578     DOI: 10.1038/tpj.2016.57

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  26 in total

1.  A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

Authors:  A-K Hamberg; M-L Dahl; M Barban; M G Scordo; M Wadelius; V Pengo; R Padrini; E N Jonsson
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

2.  A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.

Authors:  P J Avery; A Jorgensen; A K Hamberg; M Wadelius; M Pirmohamed; F Kamali
Journal:  Clin Pharmacol Ther       Date:  2011-09-28       Impact factor: 6.875

3.  Genotype-guided dosing of vitamin K antagonists.

Authors:  Elizabeth A Koller; Jeffrey C Roche; James A Rollins
Journal:  N Engl J Med       Date:  2014-05-01       Impact factor: 91.245

4.  Genotype-guided dosing of vitamin K antagonists.

Authors:  Roxana Daneshjou; Teri E Klein; Russ B Altman
Journal:  N Engl J Med       Date:  2014-05-01       Impact factor: 91.245

5.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

6.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Authors:  Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn D Ritchie; Maria G Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

7.  Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.

Authors:  Rui Nagai; Minami Ohara; Larisa H Cavallari; Katarzyna Drozda; Shitalben R Patel; Edith A Nutescu; Minoli A Perera; Wenndy Hernandez; Naoko Kaneko; Manabu Hibiya; Harumi Takahashi
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

8.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

9.  Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.

Authors:  Roxana Daneshjou; Eric R Gamazon; Ben Burkley; Larisa H Cavallari; Julie A Johnson; Teri E Klein; Nita Limdi; Sara Hillenmeyer; Bethany Percha; Konrad J Karczewski; Taimour Langaee; Shitalben R Patel; Carlos D Bustamante; Russ B Altman; Minoli A Perera
Journal:  Blood       Date:  2014-07-30       Impact factor: 22.113

Review 10.  Oral anticoagulation: a critique of recent advances and controversies.

Authors:  Munir Pirmohamed; Farhad Kamali; Ann K Daly; Mia Wadelius
Journal:  Trends Pharmacol Sci       Date:  2015-02-17       Impact factor: 14.819

View more
  9 in total

1.  Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.

Authors:  Minami Ohara; Yasuhiko Suzuki; Saki Shinohara; Inna Y Gong; Crystal L Schmerk; Rommel G Tirona; Ute I Schwarz; Ming-Shien Wen; Ming Ta Michael Lee; Kiyoshi Mihara; Edith A Nutescu; Minoli A Perera; Larisa H Cavallari; Richard B Kim; Harumi Takahashi
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 2.  An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.

Authors:  Antony Martin; Jennifer Downing; Michelle Maden; Nigel Fleeman; Ana Alfirevic; Alan Haycox; Munir Pirmohamed
Journal:  Pharmacogenomics       Date:  2017-11-02       Impact factor: 2.533

3.  Exploring public genomics data for population pharmacogenomics.

Authors:  Kleanthi Lakiotaki; Alexandros Kanterakis; Evgenia Kartsaki; Theodora Katsila; George P Patrinos; George Potamias
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

4.  Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine.

Authors:  Basim Mohammad Ayesh; Ahmed Shaker Abu Shaaban; Abdalla Asaf Abed
Journal:  Future Sci OA       Date:  2018-01-10

5.  Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.

Authors:  Nicholas L Syn; Andrea Li-Ann Wong; Soo-Chin Lee; Hock-Luen Teoh; James Wei Luen Yip; Raymond Cs Seet; Wee Tiong Yeo; William Kristanto; Ping-Chong Bee; L M Poon; Patrick Marban; Tuck Seng Wu; Michael D Winther; Liam R Brunham; Richie Soong; Bee-Choo Tai; Boon-Cher Goh
Journal:  BMC Med       Date:  2018-07-10       Impact factor: 8.775

6.  The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.

Authors:  Maor Wanounou; Chanan Shaul; Zahi Abu Ghosh; Shoshana Alamia; Yoseph Caraco
Journal:  Clin Pharmacol Ther       Date:  2022-05-05       Impact factor: 6.903

Review 7.  Warfarin Pharmacogenomics in Diverse Populations.

Authors:  Justin B Kaye; Lauren E Schultz; Heidi E Steiner; Rick A Kittles; Larisa H Cavallari; Jason H Karnes
Journal:  Pharmacotherapy       Date:  2017-09-06       Impact factor: 4.705

Review 8.  Warfarin: The End or the End of One Size Fits All Therapy?

Authors:  Munir Pirmohamed
Journal:  J Pers Med       Date:  2018-06-28

9.  CSVS, a crowdsourcing database of the Spanish population genetic variability.

Authors:  María Peña-Chilet; Gema Roldán; Javier Perez-Florido; Francisco M Ortuño; Rosario Carmona; Virginia Aquino; Daniel Lopez-Lopez; Carlos Loucera; Jose L Fernandez-Rueda; Asunción Gallego; Francisco García-Garcia; Anna González-Neira; Guillermo Pita; Rocío Núñez-Torres; Javier Santoyo-López; Carmen Ayuso; Pablo Minguez; Almudena Avila-Fernandez; Marta Corton; Miguel Ángel Moreno-Pelayo; Matías Morin; Alvaro Gallego-Martinez; Jose A Lopez-Escamez; Salud Borrego; Guillermo Antiñolo; Jorge Amigo; Josefa Salgado-Garrido; Sara Pasalodos-Sanchez; Beatriz Morte; Ángel Carracedo; Ángel Alonso; Joaquín Dopazo
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.